Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
search results for:
Agios
Search
David Schenkein resigns from Agios’ board; Moderna hires Roivant exec as chief marketing officer
4 months ago
Peer Review
Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids
4 months ago
R&D
Agios' stock drops after disclosing new liver-related safety warning in filing to FDA
6 months ago
Pharma
FDA+
Updated: FDA approves Servier’s brain cancer drug, setting up $1B payout for Agios
10 months ago
R&D
FDA+
Agios' late-stage Pyrukynd trial in kids with rare blood disorder misses primary endpoint
10 months ago
R&D
Pharma
Agios plans thalassemia filing in US after unveiling data in transfusion-dependent patients
Last year
Pharma
FDA+
Agios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement
Last year
News Briefing
Agios’ oral drug secures PhIII success in transfusion-independent thalassemia patients
Last year
R&D
Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M
Last year
Deals
R&D
Looking to expand Pyrukynd label, Agios treks toward PhIII in sickle cell disease
Last year
R&D
In final pivot from cancer to rare disease, Agios offloads its share of Tibsovo royalties for $131M
3 years ago
Deals
Amid massive turnover, Agios hires Biogen alum as new CFO; Scholar Rock, Everest Medicines lead the big CEO parade
3 years ago
Peer Review
After architecting Agios’ oncology exit and R&D pivot, Jackie Fouse hands keys to former Alexion exec
3 years ago
People
Agios CSO to depart amid layoffs as biotech looks for new drugs to license or acquire
4 years ago
People
R&D
After selling off Tibsovo and entire cancer pipeline, Agios nets first approval for new 'anchor product'
4 years ago
FDA+
Tibsovo clears another hurdle for Servier, but can it make Agios' old drug profitable?
4 years ago
R&D
Agios scores its second positive round of data for its lead pipeline drug — but that won't answer the stubborn ...
5 years ago
R&D
Agios pivots away from oncology, auctioning off cancer pipeline for $2B and shifting the spotlight in restructuring
5 years ago
Deals
1
2
3
4
Next page
Last page
latest
Most read
FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes
6 hours ago
FDA+
Grail shares jump on study results for cancer test
Yesterday
Pharma
Diagnostics
Gilead gets groundbreaking FDA approval for twice-yearly HIV prevention shot
Yesterday
Pharma
FDA+
Compounders lose case over semaglutide shortage
Yesterday
Pharma
Health Tech
see latest stream
